Linker-Payload Conjugates with Stabilizing Groups for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current linker-payload conjugates face challenges in achieving high in vivo stability and targeted efficacy against tumor cells, with issues related to premature linker cleavage and limited pharmacokinetic properties.
Innovation Solution
The development of linker-payload conjugates incorporating a stabilizing group, such as a maleimidoacetyl group, and a cleavable hydrophilic group, which enhances stability, water solubility, and resistance to aggregation, thereby improving targeted delivery and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a linker-payload conjugate is designed for targeted delivery to tumor cells, then efficacy against tumor cells is improved, but in vivo stability deteriorates due to premature linker cleavage
Solution Approach 1:
The linker is divided into distinct functional segments: a stabilizing group (maleimidoacetyl) that prevents premature cleavage, a cleavable hydrophilic group (such as glucosidase-sensitive or cathepsin-sensitive groups) that enables controlled release at the target site, and a payload attachment point. This segmentation allows the linker to simultaneously provide in vivo stability during circulation and enable targeted efficacy through site-specific cleavage.
Solution Approach 2:
The stabilizing group acts as an intermediary between the maleimide moiety and the cleavable hydrophilic group. It prevents direct interaction between the maleimide and biological nucleophiles that would cause premature cleavage, while still allowing the cleavable group to be accessed and cleaved by specific enzymes at the tumor site, thus mediating both stability and targeted release.
2Reliability
If the linker structure is optimized for stability, then in vivo stability is improved, but water solubility and resistance to aggregation worsen
Solution Approach 1:
The cleavable hydrophilic group undergoes parameter changes upon enzymatic cleavage: it transitions from a hydrophobic or amphiphilic state that provides stability to a hydrophilic state that improves water solubility. For example, glucosidase cleavage releases a glucoside group that is highly water-soluble, and cathepsin cleavage releases charged amino acid residues that enhance solubility and prevent aggregation.
3Productivity
If the linker is designed for targeted release, then efficacy in modulating tumor cell growth is improved, but pharmacokinetic properties deteriorate
Solution Approach 1:
The linker exhibits dynamic behavior: it maintains a stable, compact conformation during circulation that protects the payload and maintains appropriate pharmacokinetics, then undergoes a conformational change or cleavage event at the tumor site triggered by specific enzymes, leading to payload release and improved efficacy. The hydrophilic group's solubility changes dynamically upon cleavage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed linker-payload conjugates demonstrate enhanced in vivo stability, improved pharmacokinetics, and increased efficacy in targeting and modulating tumor cell growth, as evidenced by effective tumor shrinkage in preclinical models.
Implementation Method 1
incorporating a stabilizing group, such as a maleimidoacetyl group
Implementation Method 2
a cleavable hydrophilic group, which enhances stability, water solubility, and resistance to aggregation
Data Source
AI summary
Linker-payloads and their conjugates are disclosed.